Roquette Ventures, the venture capital arm of Roquette, is excited to announce its investment in Biograil ApS, a pioneering startup revolutionizing the oral delivery of biologics, based in Copenhagen.
This investment forms part of a new seed funding round, designed to further Biograil's disruptive technology.
Alongside Roquette Ventures, Megatrend Invest a/s joins this round of funding, contributing to a robust consortium that includes Megatrend Invest (Denmark), Verve Investment (Switzerland), High-Tech Gründerfonds (Germany), Sanner Ventures (Germany), Evonik Venture Capital (Germany) and Eli Lilly & Co. (US). This group unites a diverse range of knowledge, expertise, and resources.
Biograil stands at the forefront of biotech innovation, focusing on a revolutionary oral device for delivering biologics that would typically require injection. This advancement is set to transform patient care by offering a less invasive and more accessible treatment method. The investment will support the development of Biograil's BIONDD™ technology, aiming to redefine the standard for biologics delivery.
This investment is perfectly aligned with Roquette Venture’s investment thesis, focusing on fostering solutions that enhance health and sustainability. Furthermore, Roquette Ventures will also bring the Roquette Group's extensive expertise in pharmaceutical excipients, enhancing Biograil's efforts to advance their platform technology.
About Biograil Aps
Biograil is a Copenhagen based biotech company developing pharmaceutical products based upon the BIONDDTM device contained in a standard size capsule able to deliver active therapeutics into the gastrointestinal wall to be effectively distributed in the human body. Such therapeutics can be currently marketed products, including multi-billion-dollar injectable pharmaceuticals or new chemical entities that cannot otherwise be delivered orally. The Biograil device uses a novel mechanism to facilitate the delivery of active substances i.e., biologics efficiently into the gastrointestinal wall utilizing a proprietary platform technology manufactured by injection molding. The team behind Biograil is a combination of seasoned entrepreneurs with long experience in creating successful biotech companies as well as R&D executives behind the world’s first injection molded oral tablet approved by the FDA. Biograil has an established collaboration with Eli Lilly. The Biograil investor syndicate is formed by Megatrend Invest (Denmark), Verve Investment (Switzerland), High-Tech Gründerfonds (Germany), Sanner Ventures (Germany), Evonik Venture Capital (Germany) and Eli Lilly & Co. (US).